Oct 2026· European Journal of Public Health· Vol 36· 0 citations
TL;DR
Emerging evidence suggests CAR T-cell therapy is associated with rapid, sustained clinical remission in severe, refractory cases, particularly Systemic Lupus Erythematosus, and demonstrates promise as a novel therapeutic strategy for refractory autoimmune diseases.
Abstract
Abstract Background Systemic autoimmune diseases pose significant therapeutic challenges due to suboptimal responses and frequent relapses with conventional treatments. Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a transformative approach, offering targeted, sustained B-cell depletion. This review evaluates its efficacy and safety in refractory systemic autoimmune conditions. Methods A literature search was conducted across PubMed, Scopus, and Web of Science for studies published in recent years. Eligible studies included clinical trials, observational studies, and case series assessing CAR T-cell therapy in treatment-resistant patients. Study selection and data extraction followed systematic protocols; quality was appraised using risk-of-bias tools. A narrative synthesis was performed due to heterogeneity. Results Emerging evidence suggests CAR T-cell therapy is associated with rapid, sustained clinical remission in severe, refractory cases, particularly Systemic Lupus Erythematosus. Consistent findings include profound B-cell depletion and significant reductions in autoantibody titres. However, the evidence base is limited by small sample sizes, short follow-up, and variable treatment protocols. Reported adverse events, including cytokine-mediated inflammatory responses and infection risk, were generally manageable but represent important safety considerations. Conclusions CAR T-cell therapy demonstrates promise as a novel therapeutic strategy for refractory autoimmune diseases, with the potential to redefine treatment paradigms. However, current evidence remains preliminary. Robust, large-scale studies with long-term follow-up are essential to establish safety, durability, and generalizability in broader clinical practice. Key messages • CAR T-cell therapy shows promise for rapid and sustained remission in severe, refractory autoimmune diseases like systemic lupus erythematosus. • While promising, current evidence is limited by small samples and short follow-ups; large-scale studies are essential for clinical practice.
Background B cells play a critical role in autoimmunity through autoantibody production, plasma cell differentiation, antigen presentation, cytokine secretion, and germinal center responses. The clinical efficacy, durability, and safety profiles vary across autoimmune diseases. Therefore, the objective is to assess B-c...
Vishakha Hooda, Harsh Goel, Taruna Madan et al.· Frontiers in Immunology· 0 citations
In vivo chimeric antigen receptor (CAR) T-cell therapy directly programs endogenous T cells within the patient rather than generating the cells through conventional ex vivo manufacturing. While promising, the clinical landscape of this emerging technology is fragmented. Therefore, this systematic review evaluated...
E. Mahmoudi, Faezeh Shokrolahi, Amir Hossein Razmi Khoshkanab et al.· BMC Cancer· 0 citations